These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34439990)

  • 1. Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells.
    Damiani I; Castiglioni S; Sochaj-Gregorczyk A; Bonacina F; Colombo I; Rusconi V; Otlewski J; Corsini A; Bellosta S
    Biology (Basel); 2021 Aug; 10(8):. PubMed ID: 34439990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific targeting of HER2-positive human breast carcinoma SK-BR-3 cells by amygdaline-Z
    Moradipoodeh B; Jamalan M; Zeinali M; Fereidoonnezhad M; Mohammadzadeh G
    Mol Biol Rep; 2020 Sep; 47(9):7139-7151. PubMed ID: 32929653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Affibody-Auristatin E Conjugate With a Potent and Selective Activity Against HER2+ Cell Lines.
    Sochaj-Gregorczyk AM; Serwotka-Suszczak AM; Otlewski J
    J Immunother; 2016; 39(6):223-32. PubMed ID: 27227324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and In Vitro Evaluation of a Cytotoxic Conjugate Based on the Anti-HER2 Affibody Fused to the Fc Fragment of IgG1.
    Sochaj-Gregorczyk AM; Ludzia P; Kozdrowska E; Jakimowicz P; Sokolowska-Wedzina A; Otlewski J
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28771178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.
    Serwotka-Suszczak AM; Sochaj-Gregorczyk AM; Pieczykolan J; Krowarsch D; Jelen F; Otlewski J
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28216573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of Targeted Chemotherapy of HER2-positive Ovarian Malignant Cell Line by Z
    Siavoshinia L; Jamalan M; Zeinali M; Pourshohod A; Koushki M; Moradipoodeh B; Mohammadzadeh G
    Iran J Pathol; 2021; 16(2):109-118. PubMed ID: 33936221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
    Yaghoubi S; Gharibi T; Karimi MH; Sadeqi Nezhad M; Seifalian A; Tavakkol R; Bagheri N; Dezhkam A; Abdollahpour-Alitappeh M
    Breast Cancer; 2021 Jan; 28(1):216-225. PubMed ID: 32889587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific Targeting of HER2-Positive Head and Neck Squamous Cell Carcinoma Line HN5 by Idarubicin-ZHER2 Affibody Conjugate.
    Ghanemi M; Pourshohod A; Ghaffari MA; Kheirollah A; Amin M; Zeinali M; Jamalan M
    Curr Cancer Drug Targets; 2019; 19(1):65-73. PubMed ID: 28460618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer.
    Li H; Yu C; Jiang J; Huang C; Yao X; Xu Q; Yu F; Lou L; Fang J
    Cancer Biol Ther; 2016 Apr; 17(4):346-54. PubMed ID: 26853765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery.
    Li L; Xu MZ; Wang L; Jiang J; Dong LH; Chen F; Dong K; Song HF
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12929-12937. PubMed ID: 33378043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
    Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
    Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Dual-Payload ADC for the Treatment of HER2+ Breast and Colon Cancer.
    Mckertish CM; Kayser V
    Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells.
    Sharma S; Li Z; Bussing D; Shah DK
    Drug Metab Dispos; 2020 May; 48(5):368-377. PubMed ID: 32086295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs.
    Yin W; Xu T; Ding H; Zhang J; Bodenko V; Tretyakova MS; Belousov MV; Liu Y; Oroujeni M; Orlova A; Tolmachev V; Gräslund T; Vorobyeva A
    J Control Release; 2023 Mar; 355():515-527. PubMed ID: 36773960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
    Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
    J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors.
    Altai M; Liu H; Ding H; Mitran B; Edqvist PH; Tolmachev V; Orlova A; Gräslund T
    J Control Release; 2018 Oct; 288():84-95. PubMed ID: 30172673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency.
    Dovgan I; Ehkirch A; Lehot V; Kuhn I; Koniev O; Kolodych S; Hentz A; Ripoll M; Ursuegui S; Nothisen M; Cianférani S; Wagner A
    Sci Rep; 2020 May; 10(1):7691. PubMed ID: 32376903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy.
    Best RL; LaPointe NE; Azarenko O; Miller H; Genualdi C; Chih S; Shen BQ; Jordan MA; Wilson L; Feinstein SC; Stagg NJ
    Toxicol Appl Pharmacol; 2021 Jun; 421():115534. PubMed ID: 33852878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
    Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V
    J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.